GNPX · Genprex, Inc.

Genprex, Inc. disclosed on May 14, 2026, that its research collaborators presented positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/MafA gene therapy) at the 2026 ASGCT Annual Meeting. The study demonstrated that a single administration of GPX-002 via retrograde pancreatic duct infusion reversed hyperglycemia in Type 2 diabetic mouse models within four weeks. Key findings included improved glucose-stimulated insulin secretion, increased mature insulin granules, and a shift of β-cells toward a more mature state. Both global (CMV promoter) and β-cell-specific (RIP promoter) delivery showed efficacy, indicating the therapy directly addresses β-cell dysfunction. The press release highlighted that the approach is technically translatable to humans using endoscopic retrograde cholangiopancreatography. Genprex believes this preclinical data is a pivotal step toward a potentially transformative treatment for T2D, offering long-term glycemic control beyond symptomatic management. The filing includes forward-looking statements regarding clinical development, regulatory approvals, and the company's ability to continue as a going concern.